SFINX—a drug-drug interaction database designed for clinical decision support systems
- 875 Downloads
The aim was to develop a drug-drug interaction database (SFINX) to be integrated into decision support systems or to be used in website solutions for clinical evaluation of interactions.
Key elements such as substance properties and names, drug formulations, text structures and references were defined before development of the database. Standard operating procedures for literature searches, text writing rules and a classification system for clinical relevance and documentation level were determined. ATC codes, CAS numbers and country-specific codes for substances were identified and quality assured to ensure safe integration of SFINX into other data systems. Much effort was put into giving short and practical advice regarding clinically relevant drug-drug interactions.
SFINX includes over 8,000 interaction pairs and is integrated into Swedish and Finnish computerised decision support systems. Over 31,000 physicians and pharmacists are receiving interaction alerts through SFINX. User feedback is collected for continuous improvement of the content.
SFINX is a potentially valuable tool delivering instant information on drug interactions during prescribing and dispensing.
KeywordsDrug-drug interaction database Clinical decision support system Drug interactions
The Finnish Ministry of Health and Social Affairs, the Stockholm County Council and Karolinska Institutet, Stockholm, Sweden, for financial support.
- 9.US Food and Drug Administration (2006) Guidance for industry: drug interaction studies: study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/cder/guidance/6695dft.pdf. Accessed 2008-10-09
- 10.US Food and Drug Administration (1999) Guidance for industry: in vivo metabolism/drug interactions: study design, data analysis and recommendation for dosing and labeling. http://www.fda.gov/Cder/guidance/2635fnl.pdf. Accessed 2008-10-09
- 11.EMEA: CPMP/ICH/291/95 (1998) Note for guidance on general considerations for clinical trials. http://www.emea.europa.eu/pdfs/human/ich/029195en.pdf. Accessed 2008-10-09
- 18.Wolters Kluwer (2008) Hansten and Horn’s drug interactions analysis and management. http://www.factsandcomparisons.com. Accessed 2008-10-09
- 19.Pharmaceutical Press (2008) Stockley’s drug interactions online version. http://www.medicinescomplete.com. Accessed 2008-10-09
- 20.Wolter Kluwers (2008) Drugline. http://www.ovid.com/site/catalog/Database/2816.jsp. Accessed 2008-10-09
- 21.Thomson (2008) DRUGDEX, system provided by MICROMEDEX. http://www.thomsonhc.com/hcs/librarian/PFPUI/i2UCSoAjEX3J. Accessed 2008-10-09
- 22.NCBI (2008) Medline. http://www.ncbi.nlm.nih.gov/sites/entrez. Accessed 2008-10-09
- 23.Elsevier (2007) Embase. http://www.embase.com. Accessed 2008-10-09
- 24.LIF (2008) Swedish PDR and SPC. http://www.fass.se. Accessed 2008-10-09
- 25.Terveys (2008) Pharmaca fennica. http://www.terveysportti.fi. Accessed 2008-10-09
- 26.EMEA (2008) The European public assessment reports (EPARs). http://www.emea.europa.eu/index/indexh1.htm. Accessed 2008-10-09
- 27.Sjöqvist F (1997) A new classification system for drug interactions. Eur J Clin Pharmacol 52 (Suppl):327aGoogle Scholar
- 28.Liaw ST, Schattner P (2003) Electronic decision support in general practice. What’s the hold up? Aust Fam Physician 3211:941–944Google Scholar
- 29.Sjöborg B, Bäckström T, Arvidsson LB, Andersen-Karlsson E, Blomberg LB, Eiermann B et al (2007) Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region-bridging the gap between knowledge and practice. Int J Med Info 76(7):497–506CrossRefGoogle Scholar